Compare Cardiovascular Benefits of SGLT2 Inhibitors for Type 2 Diabetes
January 2019
SGLT2 inhibitors (Invokana, etc) are in the spotlight again.
Reps will say Invokana (canagliflozin) is now approved to reduce the risk of major CV events in adults with type 2 diabetes and CV disease...while Jardiance (empagliflozin) is only approved to reduce CV death.
Explain Invokana's approval is based on NONsignificant reductions in CV death, heart attack, or stroke...lumped into one composite outcome.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive